Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. The company said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease. Data presented at a medical meeting last month showed that about 40% of patients with advanced lung cancer on the Opdivo-Yervoy combination were alive after two years, …read more
Source:: Yahoo Finance
